Top Page
Cybin
(NEO-L:CYBN)
Cybin (CYBN) vs. iShares MSCI Canada ETF (EWC)
Cybin Business Overview & Revenue Model
Cybin Earnings Call Summary
Cybin Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | ― | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -92.53K | ― | 0.00 | -424.00K | -251.00K | -168.00K |
| EBITDA | -135.37M | ― | -142.67M | -78.58M | -47.24M | -63.67M |
| Net Income | -112.18M | ― | -113.14M | -78.08M | -47.49M | -67.63M |
Balance Sheet | ||||||
| Total Assets | 252.19M | ― | 258.62M | 302.02M | 53.90M | 92.11M |
| Cash, Cash Equivalents and Short-Term Investments | 116.53M | ― | 135.02M | 208.99M | 16.63M | 64.03M |
| Total Debt | 40.19M | ― | 0.00 | 291.00K | 0.00 | 0.00 |
| Total Liabilities | 42.25M | ― | 21.42M | 10.10M | 5.66M | 5.99M |
| Stockholders Equity | 193.40M | ― | 237.20M | 291.93M | 48.23M | 86.12M |
Cash Flow | ||||||
| Free Cash Flow | -114.32M | ― | -103.27M | -69.62M | -50.74M | -19.26M |
| Operating Cash Flow | -112.27M | ― | -101.30M | -68.91M | -47.43M | -19.03M |
| Investing Cash Flow | -2.04M | ― | -1.97M | 6.92M | -3.31M | -1.19M |
| Financing Cash Flow | 75.29M | ― | 20.20M | 254.51M | 13.56M | 35.78M |
Cybin Peers Comparison
Cybin Corporate Events
Helus Pharma, the new operating name of Cybin Inc., has rebranded to better reflect its evolution from a discovery-focused clinical-stage biotech to a commercial-ready pharmaceutical company targeting mental health disorders with its portfolio of novel serotonergic agonists. The company has transferred its U.S. stock listing from NYSE American to the Nasdaq Global Market and will trade under the ticker symbol HELP in both the United States and on Cboe Canada, as it prepares for potential commercialization of its lead NSA HLP003 for major depressive disorder, which is in Phase 3 and holds FDA Breakthrough Therapy Designation, and advances HLP004 for generalized anxiety disorder with key data readouts expected in 2026, positioning the business for a pivotal year that could reshape its market standing and deliver new treatment options for patients and value for stakeholders.
The most recent analyst rating on (TSE:CYBN) stock is a Hold with a C$0.13 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Cybin Inc. will transfer its U.S. stock market listing from NYSE American to the Nasdaq Global Market, with trading on NYSE American ending on January 2, 2026 and Nasdaq trading beginning January 5, 2026. Concurrent with the move, the company will adopt the business name Helus Pharma and change its ticker symbol to “HELP” on both Nasdaq and Cboe Canada, a rebranding that management frames as a key step in its evolution and alignment with a larger peer group of global pharmaceutical companies, potentially enhancing its visibility with investors and its positioning within the mental health therapeutics sector.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$55.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Cybin Inc. will transfer its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market, with trading on Nasdaq expected to begin January 5, 2026 under a new ticker, “HELP,” as the company adopts the business name Helus Pharma in both the U.S. and on Cboe Canada. Management positions the move as a key step in its evolution into a global pharmaceutical player, aligning the mental-health drug developer with a larger peer group on Nasdaq and potentially increasing its visibility among investors as it advances late-stage clinical programs in depression and anxiety.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$55.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Cybin announced it will move its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market, with trading on NYSE American ending on January 4, 2026 and Nasdaq trading beginning January 5, 2026 under a new ticker symbol, HELP; its Cboe Canada listing will also adopt the HELP symbol on the same date. Management framed the switch as a key milestone in Cybin’s evolution into a global pharmaceutical player, positioning the mental-health-focused drug developer alongside larger peers on a more biotech-centric exchange, a move that could enhance visibility with investors focused on innovative healthcare and potentially support future capital-raising and strategic growth initiatives.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$48.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Cybin Inc. reported its financial results for the second quarter of fiscal year 2026, highlighting a successful $175 million financing round led by biopharmaceutical investors. The company is progressing with its Phase 2 and Phase 3 clinical trials for CYB004 and CYB003, targeting GAD and MDD respectively, with key data readouts expected in 2026. The recent financing has strengthened Cybin’s cash position, enabling it to advance its late-stage programs, prepare for commercialization, and retire debt. The company is also expanding its intellectual property portfolio, which supports its competitive positioning in the neuropsychiatry sector.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$150.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Cybin announced that its Chief Business Officer, George Tziras, will present at the Jefferies Global Healthcare Conference in London, highlighting the company’s commitment to advancing mental healthcare. This participation underscores Cybin’s strategic efforts to strengthen its industry position and engage with stakeholders, potentially impacting its operations and market presence.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$150.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Cybin Inc. announced it will release its second quarter financial results and provide a business update on November 13, 2025, through a conference call and webcast. This announcement highlights Cybin’s ongoing efforts to advance its clinical programs and strengthen its position in the mental healthcare industry, potentially impacting stakeholders by showcasing its progress and financial health.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$150.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Cybin announced its participation in the Guggenheim 2nd Annual Healthcare Innovation Conference, where its Chief Business Officer, George Tziras, will engage in a fireside chat. This participation underscores Cybin’s commitment to advancing mental healthcare solutions and highlights its strategic positioning in the neuropsychiatry industry.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$150.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Cybin announced that its Chief Medical Officer, Amir Inamdar, will participate in a panel at the 2025 Milken Institute Future of Health Summit. This participation underscores Cybin’s commitment to advancing mental health treatment through innovation and highlights its strategic positioning in the neuropsychiatry industry.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$150.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Cybin announced the closing of a $175 million registered direct offering, involving the issuance of common shares and pre-funded warrants. The proceeds will be used to repay outstanding unsecured convertible debentures and to advance the company’s CYB003, CYB004, and CYB005 programs, as well as for general corporate purposes. This financing round, which includes notable investors such as Venrock Healthcare Capital Partners and OrbiMed, positions Cybin to further its research and development efforts in the mental health sector.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$150.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Cybin Inc. has announced a registered direct offering of common shares and pre-funded warrants, raising approximately $175 million. The proceeds will be used to repay existing debt and fund the company’s clinical programs, including CYB003, CYB004, and CYB005, as well as for general corporate purposes. This financing, supported by prominent biotech investors, is expected to enhance Cybin’s operational capabilities and strengthen its position in the neuropsychiatry industry.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$150.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.